An interventional study of Local Ablative Therapy and Standard first-line systemic treatment in Colorectal Cancer and Oligometastatic Disease, sponsored by Australasian Gastro-Intestinal Trials Group. Active, not recruiting at 9 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Australasian Gastro-Intestinal Trials Group · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 238 studies in Colorectal Neoplasms with a site in Australia — 63 open to participants now, 99 under way, 14 of them phase 3. Colorectal Neoplasms · Australia.
Among the 238 studies in Colorectal Neoplasms with a site in Australia, this one is the 225th largest by enrollment of the 230 interventional ones that give a count, is one of 17 that started in 2021, is one of 14 with no phase, reaches primary completion later than 11 of the 98 other live ones, and was the 164th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →63 of the 238 studies in Colorectal Neoplasms with a site in Australia are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in Australia, United States, China
Ages 18+
DEM BioPharma, Inc. · Sites in Australia
Ages 18+
XYone Therapeutics, Inc · Sites in Australia
Ages 18+
Context Therapeutics Inc. · Sites in Australia
Ages 18+
Second Life Therapeutics · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
238 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 125 · Phase 2 82 · Phase 3 53 · Phase 4 1
First in 1996; this study’s year is marked. 17 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 168 across the 230 interventional studies, 1,000 across the 5 observational. Of the 128 that completed or were terminated, 68 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 238 have an industry lead sponsor. The 10 most frequent:
Australasian Gastro-Intestinal Trials Group is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Australasian Gastro-Intestinal Trials Group has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
33 of the studies in Colorectal Neoplasms with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06337084Monopar TherapeuticsDiagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT04140526OncoC4, Inc.Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | 2026-12-31 |
| NCT06617169Monopar TherapeuticsDose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | 2027-01 |
| NCT07341737Second Life TherapeuticsSL-28 for Advanced Solid Tumours | 2027-01-01 |
Add all 33 to your calendar (.ics) → With an account.
Among the 238 studies in Colorectal Neoplasms with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic treatment for oligometastatic colorectal cancer.
Who is this study for:
Adults with unresectable oligo-metastatic colorectal who have demonstrated treatment benefit (partial response or stable disease as per RECIST criteria) after 3-4 months of standard first-line systemic treatment.
Study details
Participants will be randomly allocated to either a LAT arm, who will receive metastasis-directed LAT such as radiotherapy or thermal ablation following initial standard first-line systemic treatment, or a control arm who will receive continued first-line systemic treatment alone. Those receiving LAT will return to systemic treatment 16 weeks post-randomisation. Information on progression-free survival and treatment outcomes will be collected.
Data from this study will inform investigators of the potential benefit of local ablative therapy in the therapeutic setting for metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one metastatic lesion detected on CT +/- FDG-PET scan prior to first line systemic treatment AND on screening FDG-PET and CT scans, meeting the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A maximum of three Local ablative therapy (LAT) modalities can be administered for each participant, with a maximum of 2 modalities per organ, provided all LAT can be delivered within 12 weeks and participant can safely resume systemic treatment within 16 weeks from randomisation. After completing LAT, participant is to resume a further two to three months of first-line systemic treatment to a total of 6 months (including the initial 3-4 months of treatment). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion. The treating clinician may choose to discontinue systemic treatment following LAT for patients who have experienced prior intolerable toxicity.
Procedure: Local Ablative Therapy · Procedure: Standard first-line systemic treatment
The first-line systemic treatment will be standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
Procedure: Standard first-line systemic treatment
LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation \[radiofrequency ablation (RFA) or microwave ablation (MWA)\]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
Progression free survival (PFS)
To compare the efficacy of metastasis-directed LAT following initial standard first-line systemic treatment vs continued first-line systemic treatment alone, as measured by Progression-Free Survival (PFS)
Time frame: 12 Months from randomisation
Overall survival
To compare the efficacy of LAT following initial standard first-line systemic treatment, compared to continued first-line systemic treatment alone, as measured by Overall Survival (OS)
Time frame: 12 Months from randomisation and through study completion, an average of 1 year
Efficacy of local ablative therapy
To compare the efficacy of LAT following initial standard first-line systemic treatment, compared to continued first-line systemic treatment alone, on: 1. time to development of new metastatic lesions. 2. time to initiation of 2nd line systemic treatment.
Time frame: 12 Months from randomisation and through study completion, an average of 1 year
Time to progression following local ablative therapy
To assess the time to progression of LAT treated lesions.
Time frame: Through study completion, an average of 1 year
Systemic treatment-free interval
To compare systemic treatment-free interval between the two treatment groups.
Time frame: Through study completion, an average of 1 year
Rate of high-grade toxicities
To assess and compare rate of high-grade (Grade 3-5) toxicities between the two treatment groups.
Time frame: Through study completion, an average of 1 year
Quality of life measure
To compare quality of life measures between the two treatment groups using patient questionnaire - The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) using the 4-point ordinal scale (not at all, a little, quite a bit and very much)
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Dec 2025, 48 months.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 48 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australasian Gastro-Intestinal Trials Group